Caribou Biosciences Halts Only Remaining Allogeneic CAR-T Programs Over Funding Shortfall

Caribou Biosciences holds an off-the-shelf cell therapy backed by encouraging clinical data, alongside an FDA-agreed design for a pivotal study in advanced cases of a difficult-to-treat blood cancer. What the company does not have is the capital required to conduct that Phase 3 clinical trial.

Given these financial constraints, Caribou is halting work on that program and a second one—its only remaining therapeutic candidates. The discontinuations, announced after Tuesday’s market close, will result in job reductions and spending cuts as the Berkeley, California-based biotech explores strategic alternatives, which may include a merger, acquisition, or sale of assets.

“The Board took these actions in view of the current financing environment for allogeneic CAR-T cell therapies, which has made it increasingly challenging to secure the capital necessary to responsibly advance the Company’s allogeneic CAR-T cell therapy programs,” the company stated in a Tuesday regulatory filing.

Caribou’s allogeneic cell therapies are produced by engineering immune cells sourced from healthy donors. The process utilizes CRISPR technology; Caribou was co-founded by Jennifer Doudna, the Nobel Prize in Chemistry laureate recognized for her CRISPR discoveries. The off-the-shelf allogeneic approach was designed to provide manufacturing and therapeutic benefits over first-generation autologous CAR-T drugs, which are created by harvesting and engineering a patient’s own T cells.

Caribou’s Phase 3-ready candidate, vispacabtagene regedleucel (vispa-cel), is an allogeneic CAR-T therapy developed for relapsed or refractory B cell non-Hodgkin lymphoma. It is engineered to enhance activity and limit cell exhaustion, a known issue with autologous CAR-T therapies. The second discontinued program is CB-011, designed to target the BCMA protein to treat relapsed or refractory multiple myeloma.

Autologous therapies rely on a patient’s own T cells, which often suffer from diminished fitness and function after fighting cancer and enduring prior treatments. In contrast, allogeneic therapies begin with healthy immune cells from donors, offering the potential for superior outcomes. However, a primary challenge for all allogeneic developers is matching or exceeding the durability of autologous cell therapies. Caribou’s discontinuations mean the company will not get the chance to demonstrate these advantages.

In a research note, Leerink Partners analyst Daina Graybosch observed that Caribou’s announcement followed AbbVie’s report that its T cell engager (TCE), Epkinly, succeeded in a Phase 3 test as a first-line treatment for diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma. Graybosch noted that even as TCEs become entrenched as first-line treatments, allogeneic cell therapies retain value for patients requiring treatment after a TCE.

“This view is grounded in the real-world observation that autologous CAR-T efficacy can become compromised in patients who received prior TCE, potentially due to reduced fitness of the patient-derived starting cell product material,” she said. “By delivering an allo-CAR-T derived from a healthy donor cell source, the modality can sidestep this mechanistic liability.”

Graybosch suggested that investors who favor Caribou’s approach might consider the clinical-stage allogeneic CAR-T programs of Fate Therapeutics and AvenCell Therapeutics.

Caribou was founded in 2011 and went public ten years later, raising $304 million in an upsized IPO. At the time, vispa-cel (then known as CB-010) and CB-011 were in early clinical development. Despite strong investor interest at the IPO, the company has since faced financial and competitive headwinds. While allogeneic therapies offer manufacturing advantages over autologous ones, biopharma companies and investors are increasingly focusing on in vivo cell therapies, which involve significantly lower manufacturing costs and complexity.

Caribou is now undertaking its third restructuring in three years. In 2024, the company discontinued a preclinical natural killer cell therapy program to extend its cash runway. Last year, Caribou cut deeper, discontinuing a lupus program and another for acute myeloid leukemia, both in Phase 1 development. The company also reduced preclinical research, leaving only vispa-cel and CB-011 in the pipeline.

As of February, Caribou’s headcount stood at 97, according to the company’s annual report. In its second quarter 2026 financial report, Caribou stated its cash position was $113.8 million.

Caribou’s board of directors approved the current restructuring last Friday, the company said in the regulatory filing. The substantial reduction of the workforce will occur in the current quarter, leaving a limited number of employees to complete the strategic alternatives process and wind down the business. Expenses related to the restructuring are projected to fall between $15 million and $19 million.

Source link